Technological innovation and intellectual property rights of Kemei diagnostics
Kemei diagnostics has successfully developed a leading photochemiluminescence immunoassay system and its related products in China. This immunoassay technology fills the technical gap in this field in China. We have core technology and independent intellectual property rights in the upstream, midstream and downstream of raw materials, instruments and reagents.
Kemei diagnostics has established a complete intellectual property management system in accordance with the requirements of the national standards of the code for the management of enterprise intellectual property (GB / T 29490-2013), focusing on strengthening the intellectual property management of the group from four aspects: the creation and acquisition of intellectual property rights, rights management, rights application and rights protection. We encourage the creation of intellectual property rights and promote the technological innovation of Kemei group; make full use of intellectual property rights to improve the market competitive position of Kemei group; comprehensively protect intellectual property rights and support the sustainable development of Kemei group; systematically manage intellectual property rights and improve the core competitiveness of Kemei group.
In the past three years, the number of patent applications for Kemei diagnosis has increased year by year. As of June 30, 2019, the group has 69 valid authorized patents. At present, there are still hundreds of Chinese patent applications under review, and many PCT international patent applications have entered the United States, Europe, Japan, South Korea, Africa and other countries.
Kemei diagnostics has become the most patented enterprise in the field of photoluminescence technology in China.
